MOUNTAIN VIEW, Calif., April 5 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, announced today that Bob Korsan, M.S., M.A., Senior Scientist, will speak to members of the pharmaceutical and biotechnology industries via web conference on modeling and decision analysis on April 11, 2006 at 10:30 AM Pacific Time.
Mr. Korsan's presentation will discuss the use and strategic value of integrated modeling-simulation and decision analysis to assist with important development decisions by maximizing learning and making quantitative assessments of a compound's value. More information is available at http://www.pharsight.com/events/events_home.php .
"Model-based drug development, which is advocated by the Food and Drug Administration in its Critical Path initiative, goes well beyond PK/PD modeling to support dosing choices," said Shawn O'Connor, Pharsight President and CEO. "This presentation demonstrates the power of integrating decision analytic methods with animal and human data to support formulation selection strategy and trial sequencing in early development. Beyond this specific case example, it is becoming more evident that modeling and simulation can positively impact the development process by making it more efficient. Pharsight's modeling approach, which frequently integrates scientific-commercial considerations, can greatly improve the development cycle by providing a powerful set of quantitative techniques that inform decisions ranging from compound progression to portfolio selection."
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com .
Registered Trademarks
Pharsight(R) is a registered trademark of Pharsight Corporation.
Pharsight CorporationCONTACT: investors, Douglas Sherk, or Jennifer Beugelmans, both at+1-415-896-6820, or media, Steve DiMattia, +1-646-277-8706, all of EVCGroup for Pharsight Corporation
Web site: http://www.pharsight.com/
